Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Clazosentan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA known ✓ | P25101 | 20/20 | 0.79 |
| ▸ | EDNRB | P24530 | 17/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clazosentan SCHEMBL29379450 | 1.00 | EDNRA (0.79) | EDNRAEDNRB | |
| Clazosentan SCHEMBL29581324 | 1.00 | EDNRA (0.79) | EDNRAEDNRB | |
| Clazosentan SCHEMBL29581457 | 0.99 | EDNRA (0.78) | EDNRAEDNRB | |
| Clazosentan SCHEMBL6974629 | 0.99 | EDNRA (0.78) | EDNRAEDNRB | |
| Clazosentan SCHEMBL26662037 | 0.99 | EDNRA (0.78) | EDNRAEDNRB | |
| Clazosentan SCHEMBL6974621 | 0.99 | EDNRA (0.78) | EDNRAEDNRB | |
| SCHEMBL31656331 | 0.97 | EDNRA (0.73) | EDNRAEDNRB | |
| SCHEMBL12022325 | 0.92 | EDNRA (0.68) | EDNRAEDNRB | |
| Tezosentan SCHEMBL4524 | 0.92 | EDNRA (0.80) | EDNRAEDNRB | |
| Tezosentan SCHEMBL29409604 | 0.92 | EDNRA (0.80) | EDNRAEDNRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3169365-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OF ITCH | Westfälische Wilhelms-Universität Münster (DE) | 2017-05-24 | — | — | EP | claimed |
| WO-2015169884-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OF ITCH | WESTFAELISCHE WILHELMS-UNIVERSITAET MUENSTER (DE) | 2015-11-12 | — | — | WO | claimed |
| EP-0979822-B1 | Process for the preparation of 2-carbamoyl-pyridines | HOFFMANN LA ROCHE (CH) | 2005-11-30 | — | — | EP | claimed |
| EP-0897914-B1 | Process for the preparation of 2,5-disubstitued pyridines | HOFFMANN LA ROCHE (CH) | 2004-05-26 | — | — | EP | claimed |
| US-20030232787-A1 | Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic | DOOLEY DAVID JAMES (US) | 2003-12-18 | — | — | US | claimed |
| EP-0799209-B1 | SULFONAMIDES | HOFFMANN LA ROCHE (CH) | 2003-08-06 | — | — | EP | claimed |
| EP-1289558-A2 | COMBINATIONS OF AN ENDOTHELIN RECEPTOR ANTAGONIST AND AN ANTIEPILEPTIC COMPOUND HAVING PAIN ALLEVIATING PROPERTIES OR ANALGESIC | WARNER-LAMBERT COMPANY LLC (US) | 2003-03-12 | — | — | EP | claimed |
| WO-2001091736-A2 | COMBINATIONS OF AN ENDOTHELIN RECEPTOR ANTAGONIST AND AN ANTIEPILEPTIC COMPOUND HAVING PAIN ALLEVIATING PROPERTIES OR ANALGESIC | WARNER-LAMBERT COMPANY (US) | 2001-12-06 | — | — | WO | claimed |
| US-6004965-A | Sulfonamides | HOFFMANN-LA ROCHE INC. (US) | 1999-12-21 | — | — | US | claimed |
| EP-0799209-A1 | NOVEL SULFONAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 1997-10-08 | — | — | EP | claimed |
| WO-1996019459-A1 | NOVEL SULFONAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 1996-06-27 | — | — | WO | claimed |
| US-20230373967-A1 | A STABLE CRYSTALLINE HYDRATE OF CLAZOSENTAN DISODIUM SALT | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-11-23 | — | — | US | disclosed |
| US-20230373967-A1 | A STABLE CRYSTALLINE HYDRATE OF CLAZOSENTAN DISODIUM SALT | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-11-23 | — | — | US | disclosed |
| WO-2023111299-A1 | CLAZOSENTAN DISODIUM SALT, ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-06-22 | — | — | WO | disclosed |
| WO-2017133517-A1 | PHOSPHAMIDE DERIVATIVE, METHOD FOR MANUFACTURING THE SAME, AND USES THEREOF | 四川海思科制药有限公司 | 2017-08-10 | — | — | WO | disclosed |
| WO-2001091736-A2 | COMBINATIONS OF AN ENDOTHELIN RECEPTOR ANTAGONIST AND AN ANTIEPILEPTIC COMPOUND HAVING PAIN ALLEVIATING PROPERTIES OR ANALGESIC | WARNER-LAMBERT COMPANY (US) | 2001-12-06 | — | — | WO | disclosed |
| WO-2001049289-A1 | PHARMACEUTICAL AND VETERINARY USES OF ENDOTHELIN ANTAGONISTS | TEXAS BIOTECHNOLOGY CORPORATION (US) | 2001-07-12 | — | — | WO | disclosed |
| US-6004965-A | Sulfonamides | HOFFMANN-LA ROCHE INC. (US) | 1999-12-21 | — | — | US | disclosed |
| EP-0799209-A1 | NOVEL SULFONAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 1997-10-08 | — | — | EP | disclosed |
| WO-1996019459-A1 | NOVEL SULFONAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 1996-06-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232787-A1 | Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic | EDNRA, EDNRB, ECE1 | EDNRA 1/4885EDNRB 2/4885 |
| US-20230373967-A1 | A STABLE CRYSTALLINE HYDRATE OF CLAZOSENTAN DISODIUM SALT | SLC5A1, SLC10A1, SLC5A2 | EDNRA 595/4885EDNRB 1115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.